Phase 2 Completed N=47 Randomized Double-blind Treatment

Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.

Oropharynx Cancer

Source: ClinicalTrials.gov NCT01173692 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2021

Primary outcomePrimary: Combined AUC for Selected Patient Symptoms — 3.1; 3.7 score on a scale*week

Summary

The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.

Outcome Measures

Outcome	Result	p-value
PRIMARY Combined AUC for Selected Patient Symptoms	3.1; 3.7	—

Eligibility Criteria

Inclusion Criteria

Patients with a pathologically proven diagnosis of oropharyngeal cancer, nasopharyngeal cancer, or unknown primary cancer of head and neck in MDACC receiving radiation therapy with or without induction chemotherapy.
Patients > = 18 years old.
Patients with the above cancers, T0, TX, T1 to T3, N any, M0 receiving IMRT (to unilateral or bilateral neck) at least 64-72 Gy in 6-7 weeks as definitive treatment.
Patients must have normal renal function test and no prior renal disease: The screening cut off for serum creatinine 1.5.
Patients taking any tetracycline within the last 15 days.
Patients that are pregnant.
Patients treated with upfront radical surgery at the primary site (other than diagnostic tonsillectomy or excision).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01173692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.